Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.73% | 9.68% | -131.22% | 34.29% | 33.07% |
| Total Depreciation and Amortization | -5.96% | -6.23% | -8.51% | -26.30% | -27.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.13% | 4.09% | -44.24% | -17.68% | -27.77% |
| Change in Net Operating Assets | 124.16% | 657.32% | 1,497.92% | 86.47% | -103.10% |
| Cash from Operations | -0.22% | 25.60% | -123.46% | 39.66% | 27.62% |
| Capital Expenditure | 31.17% | -373.68% | -- | -- | -200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -135.73% | 328.06% | 211.91% | -102.04% | -86.48% |
| Cash from Investing | -146.42% | 327.86% | 211.39% | -102.04% | -87.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202,673.49% | -89.92% | -20.16% | -- | -71.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 202,673.49% | -89.92% | -20.16% | -- | -71.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,143.52% | 131.84% | -99.11% | -210.62% | -219.19% |